Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 3;13(8):1778-1785.
doi: 10.1080/21645515.2017.1331795. Epub 2017 Jun 12.

Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity

Dan A Erkes  1 , Nicole A Wilski  1 , Christopher M Snyder  1
Affiliations
Review

Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity

Dan A Erkes et al. Hum Vaccin Immunother. .

Abstract

Cytomegalovirus (CMV) is a herpesvirus that induces an extremely robust and sustained immune response. For this reason, CMV has been proposed as a vaccine vector to promote immunity to both pathogens and cancer. However, exploration of CMV as a vaccine vector is at an early stage and there are many questions. Using a mouse melanoma model, we recently found that a CMV-based vaccine induced large populations of melanoma-specific T cells, but was not effective at slowing tumor growth unless it was injected directly into the tumor. These surprising results have led us to hypothesize that CMV may be adept at modulating the tumor micro-environment through its infection of macrophages. Importantly, injection of CMV into the growing tumor synergized with blockade of the PD-1 checkpoint to clear well-established tumors. Here, we discuss our results in the context of CMV-based vaccines for pathogens and cancer.

Keywords: cytomegalovirus; intratumoral therapy; tumor associated macrophages.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic of Intratumoral CMV therapy. Tumor-associated macrophages (TAM) in tumors help to promote and drive tumor growth. After injecting CMV intratumorally, CMV infected TAMs and this correlated with a delay in tumor growth. Combining this intratumoral CMV infection of TAM with anti-PD-L1 therapy synergized to induce clearance of more than 60% of tumors and long-term protection.
Figure 2.
Figure 2.
Tumor associate macrophage and changes induced by CMV infection. A) Pro-inflammatory tumor associated macrophages (TAM) express high levels of MHC-I, MHC-II and release pro-inflammatory cytokines. These attributes can contribute to T cell activation and proliferation, and subsequent anti-tumor effects. B) Tumor progression is associated with an accumulation of anti-inflammatory TAMs, which express lower levels of MHC-I, MHC-II and proinflammatory cytokines and increase expression of anti inflammatory cytokines, leading to diminished T cell responses. Additionally, anti-inflammatory TAMS release VEGF, which induces angiogenesis, CCL2, which can induce the accumulation of anti-inflammatory macrophages, and CCL22, which can induce TREG infiltration. Together, these attributes contribute to tumor progression. C) After IT infection with MCMV, TAM became infected. CMV infection of macrophages is known to promote a shift toward a more pro-inflammatory phenotype. Additionally, CMV encodes its own virally-encoded chemokines, which attract inflammatory macrophages. Thus, although more work is needed to define the changes in TAM, we hypothesize that MCMV infection of TAMs leads to increased T cell activation and proliferation and increased recruitment of pro-inflammatory macrophages to the tumor. Together, these attributes of TAM MCMV infection may shift the tumor microenvironment from anti-inflammatory to pro-inflammatory.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: Are we there yet? Immunol Rev 2011; 239(1):27-44; PMID:21198663; https://doi.org/10.1111/j.1600-065X.2010.00979.x - DOI - PMC - PubMed
    1. Saxena M, Van TT, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity against vaccine vectors–friend or foe? Microbiology 2013; 159(Pt 1):1-11; PMID:23175507; https://doi.org/10.1099/mic.0.049601-0 - DOI - PMC - PubMed
    1. Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol 2016; 16(6):367-77; PMID:27108521; https://doi.org/10.1038/nri.2016.38 - DOI - PubMed
    1. Munks MW, Gold MC, Zajac AL, Doom CM, Morello CS, Spector DH, Hill AB. Genome-wide analysis reveals a highly diverse cd8 t cell response to murine cytomegalovirus. J Immunol 2006; 176:3760-6; PMID:16517745; https://doi.org/10.4049/jimmunol.176.6.3760 - DOI - PubMed
    1. Karrer U, Wagner M, Sierro S, Oxenius A, Hengel H, Dumrese T, Freigang S, Koszinowski UH, Phillips RE, Klenerman P. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol 2004; 78(5):2255-64; PMID:14963122; https://doi.org/10.1128/JVI.78.5.2255-2264.2004 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources